Catégorie : Publications

Legalizing MDMA-Assisted Psychotherapy for the Treatment of Trauma-Related Mental Health Disorders, Prakash THAMBIPILLAI, 2021

Legalizing MDMA-Assisted Psychotherapy for the Treatment of Trauma-Related Mental Health Disorders Prakash THAMBIPILLAI Revue YOUR,  2021, Review 8, 51-61   3, 4–methylenedioxymethamphetamine, or MDMA as it is commonly known, is classified as a “Schedule 1” substance in Canada and the United States. For decades, the compound has been shrouded by the stigma of being a dangerous party drug thought to kill brain cells and be severely addictive. However, when it was originally discovered, it was experimentally used in clinical settings as an adjunct to therapy. This idea is now resurfacing as researchers are turning back to MDMA as an innovative way to treat trauma-related [...]

Lire la suite

The Effects of Cannabinoids on Sleep, Bhanu Prakash Kolla et al., 2022

The Effects of Cannabinoids on Sleep Bhanu Prakash Kolla, Lisa Hayes, Chaun Cox, Lindy Eatwell, Mark Deyo-Svendsen , and Meghna P. Mansukhani Journal of Primary Care & Community Health, 2022, Volume 13, 1–9. Doi : 10.1177/21501319221081277 Abstract The use of cannabis products to help with sleep and various other medical conditions by the public has increased significantly in recent years. Withdrawal from cannabinoids can lead to sleep disturbance. Here, we describe a patient who developed significant insomnia leading to worsening anxiety, mood, and suicidal ideation in the setting of medical cannabis withdrawal, prompting presentation to the Emergency Department and inpatient admission. There is a limited [...]

Lire la suite

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists, Gniewko Wieckiewicz et al., 2022,

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists Gniewko Wieckiewicz, Iga Stokłosa, Maciej Stokłosa, Piotr Gorczyca and Robert Pudlo Frontiers in Psychiatry, March 2022 | Volume 13 | Article 837946 doi : 10.3389/fpsyt.2022.837946   Cannabis sativa, whose flowers are also known as marijuana or marihuana, is a recreational plant that contains many chemicals that are constantly being studied by scientists around the world. One of these substances is cannabidiol (CBD), which has gained widespread popularity on the internet as a cure for mental health problems, leading many people to use CBD to self-treat depression and anxiety. This [...]

Lire la suite

Conducting Qualitative Research With Psychedelic Psychopharmacologists : Challenges of Co-Production in an Era of Interdisciplinarity, Tehseen Noorani, 2017

Conducting Qualitative Research With Psychedelic Psychopharmacologists : Challenges of Co-Production in an Era of Interdisciplinarity Tehseen Noorani SAGE Research Methods Cases Part 2,  March 3, 2017, 1-14 Doi : 10.4135/9781526404862   Abstract From 2013 to 2015, I worked as a postdoctoral research fellow with a team of pharmacologists experimenting with psilocybin, an illegal psychoactive compound found in psychedelic mushrooms. The team had conducted an open-label clinical trial with long-term cigarette smokers, using psilocybin-assisted psychotherapy to help them quit. The smoking outcomes were very promising, occurring alongside many other profound positive life-changes. The team wanted to investigate further the mechanisms of change by which the study led [...]

Lire la suite

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972   Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]

Lire la suite

OTC Cannabidiol Products Tied to Improved Pain, Sleep, Anxiety, Liz Scherer, Medscape.com, 2022

OTC Cannabidiol Products Tied to Improved Pain, Sleep, Anxiety Liz Scherer https://www.medscape.com/viewarticle/967088?uac=292598PZ&faf=1&sso=true&impID=4065214&src=mkm_ret_220305_mscpmrk_neuro_pain Medscape Medical News © January 24, 2022   Over-the-counter cannabidiol (CBD) products appear to improve pain, sleep, and anxiety disorders, preliminary research suggests. Interim findings from the Advancing CBD Education and Science (ACES), a 100% virtual, open label, randomized controlled trial, show study participants experienced various degrees of "clinically meaningful" improvements in sleep quality, anxiety, and pain. “ACES is the largest clinical trial ever conducted on commercially available CBD products and provides first-of-its-kind real world evidence into what conditions users may experience benefit from CBD usage, whether these benefits are clinically meaningful, what attributes of CBD [...]

Lire la suite

Cannabis in the management of PTSD : a systematic review, Yasir Rehman et al., 2021

Cannabis in the management of PTSD : a systematic review, Yasir Rehman, Amreen Saini, Sarina Huang, Emma Sood, Ravneet Gill and Sezgi Yanikomeroglu AIMS Neuroscience, 2021, 8, (3), 414-434. Doi : 10.3934/Neuroscience.2021022   Abstract : Introduction : Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored cannabis effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). We also investigated harm outcomes such as adverse effects and dropouts due to adverse effects, inefficacy, and all-cause dropout rates. Methods : Our search in MEDLINE, EMBASE, PsycInfo, CINAHL, Web of Science, CENTRAL, and PubMed databases, yielded 1 eligible RCT and 10 [...]

Lire la suite

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review, Luca Steardo, Jr. et al., 2021

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]

Lire la suite

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite